thalidomide has been researched along with Hyperplasia, Reactive Lymphoid in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection." | 2.58 | HIV-Associated Psoriasis. ( Queirós, N; Torres, T, 2018) |
| "Thalidomide treatment finally led to complete remission." | 1.36 | Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. ( Beylot-Barry, M; Doutre, MS; Pham-Ledard, A; Vergier, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queirós, N | 1 |
| Torres, T | 1 |
| Pham-Ledard, A | 1 |
| Vergier, B | 1 |
| Doutre, MS | 1 |
| Beylot-Barry, M | 1 |
| Benchikhi, H | 1 |
| Bodemer, C | 1 |
| Fraitag, S | 1 |
| Wechsler, J | 1 |
| Delfau-Larue, MH | 1 |
| Gounod, N | 1 |
| de Prost, Y | 1 |
| Revuz, J | 1 |
| Bagot, M | 1 |
1 review available for thalidomide and Hyperplasia, Reactive Lymphoid
| Article | Year |
|---|---|
HIV-Associated Psoriasis.
Topics: Adrenal Cortex Hormones; Biological Therapy; Contraindications, Drug; Diagnosis, Differential; Disea | 2018 |
2 other studies available for thalidomide and Hyperplasia, Reactive Lymphoid
| Article | Year |
|---|---|
Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination.
Topics: Adolescent; B-Lymphocytes; CD3 Complex; Cyclins; DNA-Binding Proteins; Female; Hepatitis B Vaccines; | 2010 |
Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases.
Topics: Adolescent; Adult; B-Lymphocytes; Dermatologic Agents; Facial Dermatoses; Female; Humans; Male; Nose | 1999 |